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Ischaemic postconditioning: from bench to bedside …
DERICK VAN VUUREN, AMANDA LOCHNER 
Summary
The	increase	in	the	incidence	of	ischaemic	heart	disease	and	
acute	myocardial	 infarction	 (AMI)	 in	 both	 high-	 and	 low-
income	countries	necessitates	the	development	of	myocardial	
salvaging/protection	 interventions,	 to	 be	 applied	 alongside	
standard	reperfusion	 therapies.	Although	 the	phenomenon	
of	 ischaemic	 preconditioning	 (IPC)	 is	 associated	 with	 the	
desired	 protective	 capacity,	 the	 necessity	 of	 its	 application	
before	sustained	ischaemia	limits	its	clinical	potential.	
The	recently	described	phenomenon	of	postconditioning	
(postC),	or	short	cycles	of	reperfusion/ischaemia	applied	at	
the	onset	of	reperfusion,	 falls	within	 the	clinically	relevant	
time	period	 of	 reperfusion,	 but	 can	 it	 elicit	 reliable	 and	
potent	cardioprotection?	The	answer	to	this	problem	is	inti-
mately	related	to	the	question	whether	postC	can	be	trans-
lated	from	a	laboratory	technique	to	a	clinical	therapy.	
In	 this	 brief	 overview	 of	 postconditioning,	 the	 experi-
mental	 set-ups	 and	 postC	 algorithms	 utilised,	 and	 their	
associated	 outcomes	 in	 all	 animal	models	 studied	 (dog,	
rabbit,	mouse,	 rat	and	pig)	are	discussed.	The	 therapeutic	
potential	of	postC	is	also	addressed	by	discussing	reported	
preliminary	studies	on	the	efficacy	and	feasibility	of	postC	
(both	ischaemic	and	pharmacological)	in	humans.
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Ischaemic heart disease is one of the leading causes of mortality, 
especially in the developed world. According to projections,1,2 
ischaemic heart disease is set to remain a major contributor to 
global mortality rates in high-, middle- and low-income coun-
tries. Since the duration of ischaemia is one of the most impor-
tant factors determining the extent of ischaemic damage,3 rapid 
reperfusion is critical in the treatment of an unexpected myocar-
dial ischaemic incident, namely, an acute myocardial infarction 
(AMI). Despite the utilisation of effective reperfusion strategies 
such as thrombolytic treatment and percutaneous coronary 
intervention (PCI), there is still a need for the development of 
interventions to increase tissue viability during ischaemia and 
reperfusion.4 It is in this setting of reperfusion adjunct therapies 
that postconditioning (postC) is of potential importance.
Postconditioning
In 1986, Murry and colleagues5 made the surprising discovery 
that multiple, brief episodes of ischaemia, applied before a 
sustained ischaemic insult, did not contribute to ischaemic inju-
ry, but rather induced an increased tolerance against ischaemic 
damage. This phenomenon, coined ischaemic preconditioning 
(IPC), has proven to be the most robust and potent intervention 
to confer protection against ischaemia/reperfusion.6 The fact 
that IPC has to be administered before the onset of ischaemia 
has unfortunately minimised the clinical applicability of this 
intervention. 
However, it has recently been shown that a similar interven-
tion applied at the very onset of reperfusion also substantially 
limits ischaemia/reperfusion injury.7 Termed postconditioning, 
this intervention is defined as the application of brief cycles 
of reperfusion/ischaemia at the onset of reperfusion, eliciting 
cardioprotection against ischaemia/reperfusion injury.8 Targeting 
of reperfusion events by the application of an intervention 
during reperfusion, which elicits a reduction in damage (such as 
postC), is viewed as proof of the existence of reperfusion injury 
per se (ie, a separate entity from ischaemic damage).9 
Postconditioning is clinically more relevant than IPC, since 
it constitutes a potent natural protective mechanism that can be 
triggered during the clinically applicable time period of reper-
fusion. It is therefore not surprising that, since its description 
in 2003,7 much research has been done on the topic. Although 
postC has been demonstrated in all species studied (dog, rabbit, 
mouse, rat and pig), there are contradictions and uncertainties as 
to the precise postC algorithm that is the best to apply.
The aim of this review is to give a critical overview of the 
different postC protocols and algorithms (as well their associ-
ated outcomes) that have been reported in the different animal 
models studied, with the aim of identifying some of the factors 
that influence postC in the experimental setting. Following this 
evaluation of postC in the laboratory setting, the potential of 
postC in the clinical setting will also be discussed.
From the bench: postconditioning in the  
laboratory
The	canine	model
Postconditioning was first described in the in vivo dog heart, 
with an infarct-sparing effect comparable to IPC.7 In this model, 
a postC protocol of three cycles of 30 sec (3 × 30 sec) reper-
fusion and ischaemia was also associated with a decrease in 
neutrophil accumulation in the area at risk (AAR), preserved 
coronary endothelial function and a reduction in reactive oxygen 
species (ROS) generation and oxidative damage. The efficacy of 
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this 3 × 30-sec protocol to reduce damage has also been shown 
by others.10,11 Despite these positive findings, Couvreur and co-
workers12 could not show an anti-stunning effect for postC in the 
canine heart, even though they applied various protocols similar 
to the 3 × 30-sec protocol (4 × 15, 30 or 60-sec reperfusion/
ischaemia, applied after 10 min regional ischaemia). 
Fujita and colleagues13 followed a completely different proto-
col by applying a 90-min period of regional ischaemia (contrary 
to the 60 min used by others in the canine model), followed by 
a postC protocol of 4 × 60-sec reperfusion/ischaemia. Despite 
these differences, they could also illustrate a postC-mediated 
decrease in infarct size. The canine heart can therefore readily 
be protected against infarct development by the application of 
a postconditioning intervention, although a beneficial effect on 
functional recovery remains to be shown.
The	rabbit	heart
The positive outcomes found in the initial canine study7 could 
also be replicated in the next species to be postconditioned: 
the rabbit. Yang et al.14 reported a 43% decrease in infarct size, 
comparable to the infarct-sparing effects of IPC, with a postC 
protocol of either four or six cycles of 30 sec of reperfusion/
ischaemia in an in vivo model. Interestingly, they found that 
the postC intervention could still be protective, even if it was 
applied after 10 min of reperfusion. On the other hand, Downey 
and Cohen15 reported that postC had to be implemented within 
one minute of reperfusion in their rabbit model. Other research-
ers12,16 similarly found that a 4 × 30-sec protocol could decrease 
infarct size, although it did not exert an anti-stunning effect after 
10 min coronary occlusion.12 
Yang and co-workers17 went on to demonstrate postcondition-
ing in the isolated rabbit heart, illustrating that at least a measure 
of the observed protection was due to intrinsic mechanisms of 
the heart, independent of blood-borne factors. Interestingly, they 
found that the 4 × 30-sec protocol used in the in vivo model was 
less beneficial than a more rapid protocol of 6 × 10 sec of reper-
fusion/ischaemia – contrary to Darling and colleagues18 who 
found a 4 × 30-sec protocol adequate to elicit an infarct-sparing 
effect in their isolated rabbit heart model. 
Other studies have also shown a protective role for postC in 
the rabbit heart, even with the administration of different proto-
cols (Table 1). The reported infarct-sparing effects of postC, 
despite differences in algorithm, suggest that postC protection 
is robust in the rabbit heart.
The	mouse	heart
Primarily two postC protocols have been described for the 
mouse heart, namely 3 × 10 sec and 6 × 10 sec of reperfusion/
ischaemia. In the in vivo setting, several researchers have shown 
the ability of a 3 × 10-sec protocol to reduce infarct size after 30 
min of regional ischaemia.32,33 Lim and co-workers33 compared 
a 3 × 10-sec and a 6 × 10-sec protocol and found that although 
both reduced infarct size, the 3 × 10-sec protocol was slightly 
more protective than the 6 × 10-sec protocol. Interestingly, 
Boengler and colleagues34 found that although both a 3 × 10-
sec and a 5 × 5-sec protocol reduced infarct size, the 5 × 5-sec 
protocol seemed more robust in that it also exerted an infarct-
sparing effect in aged and STAT3 knock-out mice (while the 3 
× 10-sec protocol was inefficient in these models).
In the isolated heart perfusion set-up though, the 6 × 10-sec 
protocol is favoured, Kin et al.35 found that a 6 × 10-sec protocol 
was associated with an improved post-ischaemic systolic and 
diastolic function in the first minutes of reperfusion after 20 min 
of global ischaemia, in contrast to a 3 × 10-sec protocol, which 
proved ineffective. These findings are noteworthy, since they 
indicate an anti-stunning effect for postC (at least in mice). 
Confirming these results, Morrison et al.36 applied a 6 × 10-
sec protocol in their ex vivo preparation, which also elicited an 
increase in functional recovery, as well as a reduction in cardiac 
troponin I (TnI; a marker of cell damage) release. The murine 
model of postC, however, does not escape the experimental 
variability that is so common in postC research, as shown in 
Table 1.
TABlE	1.	SEVERAl	DIFFERENT	POST-C	PROTOCOlS	APPlIED	IN	SIMIlAR	IN VIVO	RABBIT	HEART	EXPERIMENTS,		
AS	WEll	AS	THREE	DIFFERENT	PROTOCOlS	IN	THE	MOuSE	HEART,	DEMONSTRATING	THE	EXPERIMENTAl		
VARIABIlITY	OF	POST-C
Authors
Experimental set-up
PostC
protocol
Outcome
ConclusionModel
Ischaemia Reperfusion
duration
Para-
meter
Results
Type Duration Control (%) PostC (%) Difference (%)
Postconditioning in the rabbit
Iliodromitis et al.19 In vivo RI 30 min 180 min 4 × 30 sec IFS 48.2 ± 4.3 45.1 ± 8.9 NS Non-protective
6 × 10 sec 20.4 ± 2.9 ↓ 57.7 Protective
Chiari et al.20 In vivo RI 30 min 180 min 3 × 10 sec IFS 41 ± 2 34 ± 3 NS Non-protective
3 × 20 sec 20 ± 3 ↓ 51 Protective
Argaud et al.21 In vivo RI 30 min 240 min 4 × 60 sec IFS 61 ± 6 29 ± 4 ↓ 52 Protective
72 h 48 ± 6 20 ± 5 ↓ 58 Protective
Unique mouse heart postconditioning protocols
Yang et al.22 In vivo RI 40 min 60 min 3 × 5 sec IFS 51 ± 2 37 ± 3 ↓ 27 Protective
Tsutsumi et al.23 In vivo RI 30 min 120 min 3 × 20 sec IFS 43.4 ± 3.3 24.1 ± 3.2 ↓ 44 Protective
RPP Pre-ischaemic: 
29.9 ± 2.6
27.5 ± 2.9 NS Maintained 
heart function
Gomez et al.24 In vivo RI 60 min 24 h 3 × 60 sec IFS 56 ± 5 39 ± 3 ↓ 30 Protective
RI: regional ischaemia; IFS: infarct size; RPP: rate pressure product (beats.min-1.mmHg.10-3); NS: non-significant.
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The	rat	heart
Despite considerable variability in protocols applied in both the 
mouse and rabbit hearts, postC was generally reported to be 
associated with a cardioprotective effect. Although the question 
as to the optimal postC intervention remains, it might not be that 
important, since the protection elicited seems to be robust in 
these animal species. The picture is, however, more complicated 
in the rat heart.
The first researchers to attempt postconditioning the rat 
heart were Kin and co-workers,37 who found in an in vivo model 
that a postC protocol of 3 or 6 × 10 sec applied immediately at 
the onset of reperfusion (after 30 min of regional ischaemia) 
led to a decrease in infarct size, creatine kinase (CK) activity, 
neutrophil accumulation in the AAR, as well as a decrease in 
oxidative-related damage [as measured by plasma malondial-
dehyde (MDA) levels] and superoxide anion generation. This 
first rat study also illustrated the importance of the immedi-
ate application of the intervention at the onset of reperfusion, 
since it was found that the postC intervention lost its protective 
effect when its implementation was delayed by one minute. Two 
other noteworthy observations were also made in this study: the 
infarct-sparing effect in the rat was less robust than had been 
described in the dog7 and rabbit;14 and the infarct-sparing effect 
of IPC in the rat heart was notably stronger than postC-associ-
ated protection. 
Despite these observations, postC had been shown to be 
possible in the rat heart and since then, several studies have 
shown the efficacy of short (in the order of 10-sec) cycles 
of reperfusion and ischaemia.25,26,38 (Table 2). Confirming the 
observation that postC is not as robust as IPC,37 Tang and 
colleagues26 found that while postC could only protect after 30 
min of coronary occlusion, IPC (12 × 2-min occlusion/reper-
fusion) could protect against infarct development after 45 and 
even 60 min of ischaemia. 
Application of longer reperfusion/ischaemia cycles (30 sec) 
also seem to be effective in eliciting protection, contrary to the 
observations reported by Tang et al.31 (Table 2). Manintveld and 
colleagues39 found that 3 × 30-sec cycles of reperfusion/ischae-
mia applied after 45 or 60 min of coronary occlusion in an in 
vivo model reduced infarct size. In their study, postC (3 × 30-, 3 
× 5- and 3 × 15-sec cycles of reperfusion/ischaemia) could not 
confer cardioprotection after 90 or 120 min of ischaemia, and 
surprisingly, significantly aggravated infarct size when applied 
after 30 or 15 min of ischaemia. These latter observations are 
contrary to expectation, but the authors argued that it illustrates 
that the duration of sustained ischaemia could also determine 
the efficacy of a postC intervention. 
Intriguingly, Tillack et al.40 successfully employed a 3 × 30-
sec protocol to decrease infarct size after 30 min of regional 
ischaemia in their in vivo model. This difference in outcome 
between these two similar experimental set-ups still remains to 
be explained. Bopassa and co-workers41 also found a 3 × 30-sec 
protocol to be cardioprotective in their isolated heart set-up, 
since it was associated with an increase in functional recovery, 
as well a reduction in the levels of markers of myocardial necro-
sis [lactate dehydrogenase (LDH), CK and TnI] in the coronary 
effluent. An intriguing difference in their protocol was the 
administration of one-minute reperfusion before the application 
of postC (in constrast to most other protocols in which postC 
was immediately applied). 
Another recent study also demonstrated the cardioprotective 
ability of the 3 × 30-sec protocol, but in this case in the isolated, 
working rat heart.42 These workers found that this intervention 
preserved collagen content, decreased free radical production, 
converted reperfusion arrhythmias into normal rhythm and 
increased functional recovery after four hours of hypothermic 
(4°C) cardioplegic arrest – illustrating the potential of postC in 
the setting of open-heart surgery.
Interestingly, and surprisingly, some studies have been 
reported which applied a postC intervention consisting of a 
single cycle of ischaemia, more than a minute in duration, after 
several minutes of reperfusion (Table 3). These mould-break-
ing studies have only been done in the setting of reperfusion 
arrhythmias and fibrillation.
TABlE	2.	POSTCONDITIONING	OF	THE	RAT	HEART	BY	APPlYING	10-SEC	CYClE	POST-C	PROTOCOlS
Authors
Experimental set-up PostC protocol Outcome
ConclusionModel
Ischaemia Reperfusion 
duration Parameter
Results
Type Duration Control PostC Difference (%)
Penna et al.25 Ex vivo
constant 
flow
GI 30 min 120 min 5 × 10 sec IFS 65 ± 4% 22 ± 4% ↓ 66 Protective
LDH release 1950 ± 100 656 ± 93 ↓ 66
15, 20, 25, 30 sec 
reperfusion with 
20, 15, 10, 5 sec 
ischaemia
IFS 20 ± 2% ↓ 69 Protective
LDH release 650 ± 60 ↓ 66
Penna et al.25 Ex vivo
constant 
pressure
GI 30 min 120 min 5 × 10 sec IFS 59 ± 5% 46 ± 2% ↓ 22 Protective
LDH release 1842 ± 77 686 ± 34 ↓ 63
15, 20, 25, 30 sec 
reperfusion with 
20, 15, 10, 5 sec 
ischaemia
IFS 45 ± 2% ↓ 24 Protective
LDH release 675 ± 59 ↓ 63
Tang et al.26 Conscious 
rat
RI 30 min 24 h 6 × 30 sec IFS 54.4 ± 2.3% 55.8 ± 3.5% NS Non-protective
6 × 10 sec 36.1 ± 5.0% ↓ 34 Protective
20 × 10 sec 28.9 ± 4.9% ↓ 47 Protective
60 × 10 sec 57.3 ± 5.4% NS Non-protective
45 min 20 × 10 sec 62.2 ± 2.4% 55.4 ± 2.4% NS Non-protective
60 min 20 × 10 sec 72.7 ± 2.2% 71.4 ± 3.4% NS Non-protective
RI: regional ischaemia; IFS: infarct size; NS: non-significant; GI: global ischaemia; LDH: lactate dehydrogenase (U/g wet weight).
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Two recent studies have further highlighted the irregularity 
and variability of the outcome of postconditioning, specifically 
in the rat heart. Dow and Kloner43 attempted to postcondition the 
in vivo rat heart after either 30 or 45 min of regional ischaemia. 
They applied various protocols: 4 × 10-, 4 × 20-, 8 × 30- and 20 
× 10-sec cycles of reperfusion/ischaemia. None of these proto-
cols could reduce infarct size, despite the successful application 
of IPC, and the previous findings in their laboratory that postC 
does reduce ventricular arrhythmias.44 One possible explanation 
for these findings may lie in the fact that they used female rats. 
Crisostoma et al.45 found that although the female rat heart 
can be postconditioned (postC protocol: 6 × 10-sec cycles), this 
protection was dependent on the degree of ischaemic injury. In 
their ex vivo model, male hearts were postconditioned after 20 
and 25 min of global ischaemia, while female hearts could only 
be protected after 20 and not 25 min of ischaemia. 
Kaljusto and co-workers46 also experienced problems post-
conditioning the rat heart. In their study they investigated rats 
and mice, both in vivo and ex vivo, with the goal of develop-
ing a robust postC protocol. Although they could demonstrate 
cardioprotection in mice, only in one laboratory (of two) were 
they able to elicit cardioprotection in the in vivo rat model (with 
a protocol of 3 × 10-sec reperfusion/ischaemia after 30 min of 
regional ischaemia). In the isolated rat heart they investigated 
various protocols: 3 × 10-, 3 × 30- or 2 × 60-sec cycles of reper-
fusion/ischaemia following 30 min of global ischaemia; while 
after 40 min regional ischaemia they applied a 3 × 10-sec, as 
well as a 6 × 10-sec cycle protocol. They could, however, not 
induce an infarct-sparing effect with any of these protocols.
The rat heart can indeed therefore be postconditioned, 
although the precise optimal protocol with which cardioprotec-
tion can be achieved is still an unresolved question. To date, 
we do not have an explanation for the reported variability in 
outcomes. It could be that with regards to the rat heart, there 
are confounding factors that have not yet been identified. In 
our laboratory, for example, we found that postC only elicited 
an infarct-sparing effect when it was applied within a narrow 
temperature range around 37°C.47
The	pig	heart
Despite the inconsistent results found in the rat heart, postC 
experiments in the pig heart seemed to cause the most concern. 
The first article published on postC in the pig heart did not 
report success: Schwartz and Lagranha48 applied a protocol of 
3 × 30-sec reperfusion/ischaemia in their in vivo porcine heart 
model of regional ischaemia (30 min of coronary occlusion). 
This protocol could, however, not limit infarct size, although 
IPC could confer cardioprotection in this model. These initial 
findings raised questions as to whether all mammal species 
could be postconditioned. 
Iliodromitis et al.49 subsequently evaluated the efficacy of the 
protocol applied by Schwartz and Lagranha.48 They compared a 
4 × 30-sec protocol with an 8 × 30-sec cycle protocol, applied 
after 60 min of coronary ligation, in the in vivo model. The 8 
× 30-sec protocol elicited an infarct-sparing effect. The authors 
speculated that the total time of postC intervention (four vs 
eight minutes) might explain these differences, since in the 
longer protocol, the heart was exposed to the protective postC 
trigger(s) for a more substantial period of time. Doubt is, howev-
er, cast on the importance of the total time of postC intervention 
by studies that have recently been reported using short periods 
of postC (Table 3).
Unfortunately, the reason(s) why the initial study in the 
TABlE	3.	uNIQuE	POST-C	PROTOCOlS	APPlIED	IN	THE	RAT	HEART	TO	ElICIT	PROTECTION	AGAINST		
REPERFuSION	ARRHYTHMIA	AND	FIBRIllATION,	AS	WEll	AS	POST-C	PROTOCOlS	REPORTED	TO	BE		
CARDIOPROTECTIVE	IN	THE	PIG	HEART.	EACH	OF	THESE	PORCINE	STuDIES	uTIlISED	DIFFERENT	POST-C		
PROTOCOlS	AND	EXPERIMENTAl	DESIGNS
Authors
Experimental set-up
PostC 
protocol
Outcome
ConclusionModel
Ischaemia Reperfusion 
duration Parameter
Results
Type Duration Control PostC Difference (%)
Postconditioning the rat heart: unique protocols 
Galagudza et al.27 Ex vivo RI 30 min 30 min 15 min 
reperfusion 
+ 2 min GI
Ventricular 
fibrillation
During postC ischaemia: conversion 
of VF; onset of stable, regular rhythm 
after postC
Anti-fibril-
lation 
effect
Sasaki et al.28 Ex vivo 
(working 
model)
GI 15 min 20 min 1 min 
reperfusion 
+ 5 min GI
Arrhythmias Termination of ventricular arrhythmia, 
thus shorter duration of arrhythmia in 
postC hearts
Anti- 
arythmic 
effect
Recently reported protective postC protocols in the pig heart
Jiang et al.29 In vivo RI 75 min 180 min 3 × 30 sec IFS 45 ± 5% 12 ± 4% ↓ 73 Protective
Skyschally et al.30 In vivo Low flow 90 min 120 min 6 × 20 sec IFS 33.8 ± 4.4% 19.5 ± 2.9% ↓ 42.3 Protective
Zhao et al.31 In vivo RI 180 min 120 min 6 × 10 sec IFS 98.5% 76.1% ↓ 22.7 Protective
No-reflow area 81.3% 54.3% ↓ 33.2
HR 108 ± 6 107 ± 9 NS
LVSP 109 ± 3 111 ± 2 ↑ 2
LVEDP 6.1 ± 1.6 4.9 ± 1.9 ↓ 19.7
+ dp/dt 2287 ± 551 2759 ± 492 ↑ 21
− dp/dt 2112 ± 242 2319 ± 183 ↑ 10
CO 1.34 ± 0.25 1.94 ± 0.31 ↑ 44.78
RI: regional ischaemia; IFS: infarct size; NS: non-significant; GI: global ischaemia; VF: ventricular fibrillation; LVSP: left ventricular systolic 
pressure (mmHg); LVEDP: left ventricular end-diastolic pressure (mmHg); ± dp/dt: maximal change rate of left ventricular pressure rise and fall 
(mmHg/sec); CO: cardiac output (l/min).
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porcine model could not show cardioprotection is still unknown. 
Should the findings made by Manintveld et al.39 namely, that a 
too-short ischaemic duration could render postC non-cardiopro-
tective be extrapolated to pigs, it might also be that Schwartz 
and Lagranha48 applied a suboptimal period of regional ischae-
mia (too short) to successfully elicit postC protection. It is note-
worthy that all the studies that have reported cardioprotective 
postC in pigs applied a longer index ischaemia (see Table 3).
Considerations	to	remember	when		
postconditioning
The many studies done thus far on postconditioning clearly 
show that it is a very real cardioprotective intervention that can 
be induced in all species tested: dog, rabbit, mouse, rat and pig. 
The numerous variations in experimental set-up, postC protocol 
applied and postC efficacy, even within species, are however 
notable and demonstrate the variability of the phenomenon. 
Therefore, the existence of a reperfusion intervention that can 
salvage myocardium is undisputable, but reliable stimulation 
of this effect by the application of cycles of reperfusion and 
ischaemia (postC) seems to be hampered by various confound-
ers (many of which might still be undefined).
Several variables can, however, be identified, which seem to 
be of importance in determining the efficacy of a postC protocol 
in animal models:
● The animal species being tested. Despite the phenomenon 
being described in all species, it does seem as if it is more 
difficult to elicit postconditioning in the rat.43,46 In a recent 
review, Vinten-Johansen et al.50 speculated that the observed 
species differences may be due to differences in the rate 
and degree of ischaemia/reperfusion injury development in 
different animal species. These parameters are determined 
by factors such as myocardial metabolism, endogenous anti-
oxidant defences and the role of inflammatory cells during 
reperfusion.50
● Gender could also play a role. Since only one study has been 
reported on this subject,45 there is a need for more research 
into the importance of this variable.
● Differences in the endpoints utilised also complicate the 
interpretation of results. Supplementation of the routinely 
used endpoints of functional recovery and infarct size with 
standard biochemical parameters indicative of damage (such 
as creatine kinase and lactate dehydrogenase release) could 
facilitate comparison of results.
● The time lapse between the end of sustained ischaemia and 
the actual onset of the postC intervention. Although some 
researchers have successfully applied a postC intervention 
after a period of reperfusion,14,41 postC is generally applied 
as soon as possible after ischaemia.
● Duration of the reperfusion/ischaemia cycles. Although 
these cycles are rarely more than 60 seconds, it does seem 
as if the postC intervention is quite sensitive to even small 
changes in cycle duration.
● The number of cycles. The total duration of postC inter-
vention (determined by both the duration and numbert of 
cycles) might also be of importance,49 although the literature 
does show considerable variability in this regard.
● The duration of sustained ischaemia. This variable might 
not be as straightforward as expected39 and needs further 
investigation. If the efficacy of postC is partly determined 
by the duration of prior ischaemia, it could complicate the 
implementation of postC in the clinical setting.
Postconditioning	in	cell	culture
Although animal models are very useful for investigation of a 
phenomenon in a natural physiological setting, the utilisation of 
cell cultures is essential for determination of the mechanisms 
involved. This approach has also been recruited for the inves-
tigation of postC (Table 4). Although only three studies have 
been published on postC in isolated cells and cell culture, these 
studies all report that postC elicits protection against hypoxia/
reoxygenation damage. Interestingly, all three studies utilised 
similar postC protocols (two or three cycles of five minutes’ 
hypoxia/reoxygenation) to elicit this protection. The increase 
in cycle duration (from seconds in animals to minutes in cells) 
could be explained by the difference in metabolic rate: the meta-
bolic rate of isolated cells and cell cultures is substantially lower 
than that of hearts in vitro or in vivo.51
TABlE	4.	SuMMARY	OF	STuDIES	REPORTED	ON	THE	FEASIBIlIlTY	OF	POST-C	IN	CEllulAR	PREPARATIONS
Authors Cell type Hypoxia
Re- 
oxygen-
ation PostC Comments
Sun et al.51 Neonatal 
rat cardio-
myocytes
3 h (hypoxic 
incubator: 
95% N2  
5% CO2)
6 h 3 × 5 min 
(switching between 
normoxic and 
hypoxic incubators)
PostC reduced cell death (PI staining and LDH release)
Reduced ROS generation
Reduced intracellular and mitochondrial Ca2+
Sun et al.52 Neonatal 
rat cardio-
myocytes
3 h 6 h PostC reduced apoptosis and DNA fragmentation
Associated with: ↓ superoxide generation, ↓ JNK and p38 MAPK activity, 
↓ TNF-α release, ↓ caspase 3 and 8 activity, ↓ Bax
Zhao et al.53 H9c2 
cardiac 
muscle 
cells
8 h 3 h 3 × 5 min PostC reduced number of apoptotic cells and DNA fragmentation
Associated with: ↓ cytochrome C release, ↓ loss in mitochondral 
membrane potential and inhibition of mPTP, ↓ Bax and ↑ Bcl-2 in mito-
chondria, ↑ phospho-PKB/Akt and phospho-ERK in isolated mitochondria
Wang et al.54 Isolated 
rat cardio-
myocytes
2 h 3 h 2 × 5 min 
(switching between 
normoxic and 
hypoxic incubators)
PostC increased cell viability (assessed with trypan blue staining) and 
decreased LDH release and apoptosis
Associated with reduced ONOO– generation following hypoxia/ 
reoxygenation
PI: propidium iodide; LDH: lactate dehydrogenade; ROS: reactive oxygen species; JNK: c-Jun NH2-terminal kinase; p38 MAPK: p38 mitogen-
activated protein kinase; TNF-α: tumour necrosis factor-α; mPTP: mitochondral permeability transition pore; PKB: protein kinase B; ERK: 
extracellular signal-regulated kinase; ONOO–: peroxynitrite.
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Mechanisms behind postconditioning
Despite the variability in the postC protocols utilised, several 
gains have been made in understanding the mechanism of 
postC-associated protection – especially since the large body of 
work done on IPC has established a firm base for investigations 
into cardioprotective interventions. Although the mechanisms 
whereby postC and IPC elicit cardioprotection is beyond the 
scope of this review, the role-players identified in IPC that have 
influenced postC research will briefly be discussed, as well as 
current views regarding the mechanism of postC.
Ischaemic	preconditioning:	setting	the	stage	for	
postconditioning
For a detailed review on the mechanisms implicated in IPC, 
see Yellon and Downey.6 The intracellular mechanisms at work 
in IPC have been conceptualised as a ‘trigger–mediator–end-
effector’ pathway. The triggering phase entails the activation of 
protective cascade(s) during the actual preconditioning inter-
vention, prior to ischaemia. Some triggers identified in IPC have 
also been implicated in postC, for example, adenosine,55 brady-
kinin56 and free radicals.57,58 The borders dividing ‘triggers’, 
‘mediators’ and ‘end-effectors’ have however become blurred, 
since some molecules and pathways have been implicated as 
triggers, and also as mediators and end-effectors. 
In this regard, both the MEK 1/2 (MAPK/ERK kinases)–
ERK 1/2 (extracellular signal-regulated kinase)59 and the PI3-
kinase (phospatidylinositol 3-kinase)–PKB (protein kinase B)/
Akt pathways60,61 have been implicated in the triggering phase of 
IPC, as well as during reperfusion after sustained ischaemia.62 In 
fact, Hausenloy et al.63 reported that activation of both pathways 
during reperfusion is necessary for IPC to confer protection. 
The possible downstream end-effector of these pathways, the 
mitochondrial permeability transition pore (mPTP),64 has also 
been implicated before and after ischaemia. Brief, low-conduct-
ance opening of the mPTP during the conditioning stage of IPC 
(ie, prior to ischaemia) has been implicated in protection, possi-
bly by mediating ROS-dependent protection65 (although this has 
been challenged by Halestrap et al.66). It has also been shown 
that IPC inhibits mPTP opening during reperfusion,67,68 thereby 
eliciting cardioprotection. 
It is especially these role players that have been implicated 
in IPC during reperfusion, ie, the MEK 1/2–ERK 1/2 and PI3-
kinase–PKB/Akt pathways, as well as the mPTP, which seem to 
be vitally important in postC-mediated protection. The mecha-
nism is summarised in Fig. 1 and is discussed in the follow-
ing section (also reviewed by Zhao and Vinten-Johansen,69 
Hausenloy and Yellon,70 and Tissier et al.4).
Postconditioning
The intermittent initial reperfusion associated with postC leads 
to a state of transient acidosis,13 inhibiting the formation of the 
mPTP,71 which has been implicated in cell death. Concurrent 
with the maintenance of acidosis, intermittent reperfusion also 
causes the retention of triggering molecules (such as bradyki-
nin,72 opioids73 and adenosine17,35) within the myocardium, which 
then activates their respective receptors to activate a protective 
signalling pathway(s). This pathway(s) seems to be redox sensi-
tive, since the administration of free radical scavengers either 
before or during the postC intervention abrogates its cardiopro-
tective effects, implying a vital role for oxygen delivery during 
the postC intervention.72,74,75 Although it is redox sensitive, postC 
is also associated with a reduction in free radical generation, 
compared to control hearts.7,11,37 
As has been speculated by others,72,74,75 the precise effect of 
free radicals in reperfusion might be dependent on the ROS 
species, amount, timing and cellular compartment involved. In 
this regard, it is noteworthy that opening of the mitochondrial 
ATP-dependent potassium channel (mK+ATP channel), which has 
been shown to be associated with postC protection,14 has been 
implicated in the generation of triggering free radicals,72,74 as well 
as the activation of postC-associated protective pathways.76
Following these triggering events, postconditioning recruits 
the so-called RISK (reperfusion injury salvage kinase) pathway, 
which includes both the MEK 1/2–ERK 1/213,14,18,36 and PI3-
kinase–PKB/Akt13,14,36,40,77 pathways (for a review on RISK in 
ischaemia/reperfusion see reference 78). These kinases in turn 
inhibit the opening of the mPTP via the inhibitory phosphoryla-
tion of GSK3β (glycogen synthase kinase 3β).21,40,41,77 
Other signalling kinases have also been implicated in the 
transduction of pro-survival signals, such as protein kinase C 
(PKC),74 nitric oxide synthase (NOS) (which has been shown 
to be downstream of PI3-kinase activation),14,25,39,77,79 guanylyl 
cyclase (GC)17,25 and protein kinase G.80 The end-result is that 
by the time the pH has normalised in the cells, the survival 
kinases have been activated to ensure that the mPTP remains 
Figure 1. Overview of the intracellular mechanisms iden-
tified to be involved in the cardioprotective mechanism of 
postC. The intermittent reintroduction of perfusion leads 
to transient acidosis, which keeps the mPTP closed until 
the presence of triggering molecules, combined with 
oxygen, activate pro-survival pathways that maintain the 
mPTP in a closed conformation after normalisation of 
the pH. In this model, the mitochondria serve as primary 
end-effectors of protection. O: opioids; A: adenosine; 
B: bradykinin; MEK 1/2: MAPK/ERK kinases; ERK 1/2: 
extracellular signal-regulated kinase; PI3-kinase: phos-
patidylinositol 3-kinase; PKB: protein kinase B; GSK3β: 
glycogen synthase kinase 3β; PKC: protein kinase C; 
NOS: nitric oxide synthase; GC: guanylyl cyclase; mK+ATP-
channel: mitochondrial ATP-dependent potassium chan-
nel; STAT3: signal transducer and activator of transcrip-
tion 3; TF: tissue factor.
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closed.81 Keeping the mPTP in a closed conformation is vital, 
since opening of the pore favours cell death – via either apop-
tosis (mediated by released cytochrome C and outer membrane 
rupture), or necrosis [due to a loss of mitochondrial membrane 
potential leading to the uncoupling of oxidative phosphorylation 
and an eventual loss of adenosine triphosphate (ATP)].82 Signal 
transducer and activator of transcription 3 (STAT3)34 has also 
been implicated in postC protection. 
Besides these intracellular mechanisms, the initial studies 
on postC in the in vivo set-up also reported that postC attenu-
ated the inflammatory response, as observed in the reduction 
in tissue oedema and neutrophil accumulation in the area at 
risk.7,10,11,37 These latter two observations could be contributory 
to the reduction in no-reflow area associated with postC.31 PostC 
has also been shown to be associated with a reduction in the 
expression of tissue factor (TF) and the inhibition of thrombin 
activity in the area at risk.29 PostC cardioprotection has also 
been linked to the preservation of coronary artery endothelial 
function.7
Postconditioning, therefore, clearly recruits various mecha-
nisms to exert its cardioprotective effects. It is this ‘pleiotropic’ 
effect of the postC intervention that renders it effective in exert-
ing cardioprotection, and also increases its appeal as a possible 
intervention in the clinical setting of myocardial ischaemia/
reperfusion.
To the bedside: postconditioning in the  
clinical setting
In light of the above-discussed variations in the efficacy of 
postC in the laboratory, one would be forgiven for expecting the 
phenomenon to remain in the realm of laboratory science for 
the time being. 
The potential of postC to protect human tissue has, however, 
been demonstrated in two laboratory-based studies. By monitor-
ing flow-mediated dilation of the brachial artery as functional 
endpoint, Loukogeorgakis et al.83 demonstrated that both 3 × 
30-sec and 3 × 10-sec cycles of ischaemia/reperfusion can be 
used to decrease transient functional damage after a 20-min 
ischaemic insult on the forearm of test subjects. Sivaraman and 
co-workers84 investigated the ability of a 4 × 30-sec and 4 × 
60-sec protocol to protect isolated human atrial trabeculae from 
functional damage following 90 min of simulated ischaemia 
(paced at 3 Hz), and 120 min of simulated reperfusion (paced 
1 Hz). They found that only 4 × 60 sec induced protection, 
which was dependent on PI3-kinase and MEK 1/2 activity (in 
agreement with animal model studies).
Even prior to these studies, the existence of a cardioprotec-
tive intervention applicable at the clinically relevant time-point 
of reperfusion has energised research into the possibility of 
translating this phenomenon into a clinically viable therapy.
PostC:	a	mechanical	intervention
In 2005, Laskey85 published a pilot study in which he investi-
gated the effects of a preconditioning-like intervention applied 
in reperfusion. This study focused on patients presenting with 
an acute myocardial infarct, receiving percutaneous coronary 
intervention. In all patients, flow greater than TIMI grade 0–1 
was established by minimum intervention in the infarct-related 
artery. Following initial reperfusion, patients received either a 
conditioning intervention (ie, two 90-sec balloon inflations in 
the stenotic artery, divided by three to five min of reperfusion), 
or usual care, which entailed a single 90-sec inflation at the 
same time as the second inflation in the conditioned group. All 
patients experienced relief of angina, a decrease in stenosis to 
less than 10% and coronary flow greater than TIMI grade 2. 
In this study, Laskey85 found that the preconditioning-like 
stimulus was associated with favourable changes in electrocar-
diographic and coronary haemodynamic markers. Although it is 
questionable if this study really applied a true postC interven-
tion, it certainly illustrated the potential for postconditioning in 
humans. This potential for postC protection was confirmed by a 
retrospective analysis of patients who had received angioplasty 
after presenting with myocardial infarction.86 It was found that 
four or more balloon inflations at reperfusion were associated 
with less peak creatine kinase release than when between one 
and three inflations were applied. 
Four studies have been reported that investigated postC in 
humans in the clinical setting. Staat and co-workers87 applied a 
postC protocol of four cycles of one-minute reperfusion/ischae-
mia at the onset of reflow, after angioplasty. This was achieved 
by inflating and deflating the angioplasty balloon upstream of 
the implanted stent (to avoid damaging the stent, as well as to 
prevent thrombus embolisation). This intervention decreased 
infarct size (as measured by the area under the creatine kinase 
curve) after 72 hours of reperfusion, illustrating the feasibility 
and cardioprotective ability of postC in the human heart. 
The question whether postC permanently protects tissue 
or merely delays damage was adressed by Yang et al.88 They 
applied a postC protocol of 3 × 30 sec of reperfusion/ischaemia 
in patients undergoing PCI, by deflating and inflating the angi-
oplasty balloon. They confirmed the reduction in infarct size 
observed by Staat et al.87 but by using nuclear imaging they also 
observed a sustained decrease in infarct size after seven days of 
reperfusion. 
Applying a similar protocol, Ma and co-workers89 found that 
postC was associated with a decrease in blood levels of MDA 
and CK – illustrating a decrease in free radical-mediated cell 
injury. They also reported an increase in microcirculation reper-
fusion, peripheral artery endothelial function and left ventricular 
wall motion (measured eight weeks after PCI).  Recently Luo 
et al.90 demonstrated that a 3 × 30-sec postC protocol (adminis-
tered by opening and closing the aortic clamp) in the setting of 
cardiac surgery (specifically, valve replacement) was associated 
with a reduction in myocardial necrosis (determined by measur-
ing CK–MB levels).
The few studies that have been done on postC in the clinical 
setting therefore indicate that the human heart can be postcon-
ditioned.
Pharmacological	postconditioning
The sensitivity of the postC intervention for various factors 
(as illustrated in the laboratory), as well as the risks that are 
associated with the manipulation of coronary flow in high-
risk patients with probable unstable atherosclerotic lesions are 
factors that could limit the application of ischaemic postC in the 
clinical setting. A primary focus in postC research is therefore 
to identify pharmacological mimetics, which could be admin-
istered in reperfusion to stimulate a more reliable and risk-free 
form of cardioprotection. In this respect, various candidate 
compounds have come to light, such as adenosine35 and its 
receptor agonists,91 bradykinin,71,91 B-type natriuretic peptide,92 
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volatile anesthetics such as isoflurane20 and others.4 
A recent study has shown the potential of pharmacological 
postC to confer cardioprotection in the human heart. Jin and 
co-workers93 reported that administration of adenosine (1.5 mg/
kg) within one minute of aorta cross-clamp removal after heart 
valve replacement surgery was associated with a significant 
reduction in cardiac troponin I release at 12 and 24 hours after 
cross-clamp removal.
Conclusion
The description of the protective ability of postC, an interven-
tion applied during reperfusion, has indeed energised research 
on the effects of ischaemia/reperfusion and myocardial salvage 
during reperfusion after the alleviation of ischaemia. In this 
article, a systematic and critical overview was given of the 
application and success of postC in several animal models. A 
close look at this promising intervention reveals various prac-
tical considerations that should be taken into account when 
designing a study on postC, and which are therefore important if 
postC is to progress convincingly from basic science to standard 
clinical care.
In fact, the variability in postC protocols applied is disturb-
ing and either indicates a robustness in the protection of postC 
(since various protocols elicit protection in the same species), 
or a lack of reproducibility between studies (since different 
laboratories found it necessary to utilise different protocols to 
elicit protection). This lack of consistency in experimental set-
up and efficacy is a problem that could hamper future research, 
especially into the clinical applicability of postC. Multi-centre 
laboratory studies (such as reported by Kaljusto et al.46) could 
be a way to address this problem.
Despite the experimental problems experienced, a great deal 
of insight has been obtained into the mechanisms of postC 
cardioprotection. PostC manoeuvres have also been shown to 
confer a degree of protection in humans, illustrating clinical 
promise. Taken together, these observations indicate that a 
reperfusion-based intervention, decreasing ischaemic/reper-
fusion damage through alterations in the intracellular milieu is 
feasible and does exist. 
In the light of the variability in ischaemic postC, as demon-
strated in various laboratory studies, we suggest that pharma-
cological reperfusion therapies, harnessing the mechanisms 
associated with ischaemic postC, is the best way forward in 
translating laboratory myocardial salvaging to clinical ischae-
mia/reperfusion treatment. 
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